Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Jan 5, 2022
- Accession no.
- 0001209191-22-001426
- Filed
- Jan 5, 2022
- Trade date
- Dec 3-17, 2021
- Filing delay
- 33 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.63K. It was filed 33 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (Vice Chairman & COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 3, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +500 | $1.54 | +$770 | 256,074 | Direct | |
| Dec 10, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +200 | $1.74 | +$348 | 256,274 | Direct | |
| Dec 13, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +500 | $1.52 | +$760 | 500 | Indirect | |
| Dec 17, 2021 | Common stock, $0.001 par value | PPurchaseAcquired | +500 | $1.50 | +$750 | 1,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.